CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 3098
Citations: Bibtex RefMan EndNote GB/T7714
Chenxi GAO, Jinming SHI, Jingxin ZHANG, Yin LI, Yi ZHANG. Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1[J]. Journal of Zhejiang University Science B, 2022, 23(2): 164-170.
@article{title="Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1",
author="Chenxi GAO, Jinming SHI, Jingxin ZHANG, Yin LI, Yi ZHANG",
journal="Journal of Zhejiang University Science B",
volume="23",
number="2",
pages="164-170",
year="2022",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2100392"
}
%0 Journal Article
%T Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1
%A Chenxi GAO
%A Jinming SHI
%A Jingxin ZHANG
%A Yin LI
%A Yi ZHANG
%J Journal of Zhejiang University SCIENCE B
%V 23
%N 2
%P 164-170
%@ 1673-1581
%D 2022
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2100392
TY - JOUR
T1 - Chemerin promotes proliferation and migration of ovarian cancer cells by upregulating expression of PD-L1
A1 - Chenxi GAO
A1 - Jinming SHI
A1 - Jingxin ZHANG
A1 - Yin LI
A1 - Yi ZHANG
J0 - Journal of Zhejiang University Science B
VL - 23
IS - 2
SP - 164
EP - 170
%@ 1673-1581
Y1 - 2022
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2100392
Abstract: ovarian cancer is the third-most-common malignant reproductive tumor in women. According to the American Cancer Society, it has the highest mortality rate of gynecological tumors. The five-year survival rate was only 29% during the period from 1975 to 2008 (
[1]AlkadyMM, Abdel-MesseihPL, NosseirNM, 2018. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem, 37(3):313-319.
[2]BarbolinaMV, 2018. Molecular mechanisms regulating organ-specific metastases in epithelial ovarian carcinoma. Cancers (Basel), 10(11):444.
[3]ChangCH, QiuJ, O'SullivanD, et al., 2015. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162(6):1229-1241.
[4]ChiJY, WuZH, ChoiCHJ, et al., 2018. Three-dimensional adipose tissue imaging reveals regional variation in beige fat biogenesis and PRDM16-dependent sympathetic neurite density. Cell Metab, 27(1):226-236.e3.
[5]ClarkCA, GuptaHB, SareddyG, et al., 2016. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res, 76(23):6964-6974.
[6]DrakesML, StiffPJ, 2018. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers (Basel), 10(9):302.
[7]El-SagheerG, GayyedM, AhmadA, et al., 2018. Expression of chemerin correlates with a poor prognosis in female breast cancer patients. Breast Cancer (Dove Med Press), 10:169-176.
[8]FreemanGJ, LongAJ, IwaiY, et al., 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192(7):1027-1034.
[9]Garcia-DiazA, ShinDS, MorenoBH, et al., 2017. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep, 19(6):1189-1201.
[10]GhallabNA, ShakerOG, 2017. Serum and salivary levels of chemerin and MMP-9 in oral squamous cell carcinoma and oral premalignant lesions. Clin Oral Investig, 21(3):937-947.
[11]GhebehH, MohammedS, Al-OmairA, et al., 2006. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 8(3):190-198.
[12]GoralskiKB, JacksonAE, McKeownBT, et al., 2019. More than an adipokine: the complex roles of chemerin signaling in cancer. Int J Mol Sci, 20(19):4778.
[13]HamanishiJ, MandaiM, IwasakiM, et al., 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA, 104(9):3360-3365.
[14]HoY, WangSH, ChenYR, et al., 2019. Leptin-derived peptides block leptin-induced proliferation by reducing expression of pro-inflammatory genes in hepatocellular carcinoma cells. Food Chem Toxicol, 133:110808.
[15]HoffmannM, RakA, PtakA, 2018. Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol Lett, 291:61-69.
[16]IbrahimMM, 2010. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev, 11(1):11-18.
[17]IshikawaM, KitayamaJ, NagawaH, 2004. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res, 10(13):4325-4331.
[18]KumarJD, KandolaS, TiszlaviczL, et al., 2016. The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells. Br J Cancer, 114(10):1152-1159.
[19]KumarJD, AolymatI, TiszlaviczL, et al., 2019. Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2. Oncotarget, 10(2):98-112.
[20]LiJJ, YinHK, GuanDX, et al., 2018. Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis. Br J Cancer, 118(10):1337-1348.
[21]MaineCJ, AzizNHA, ChatterjeeJ, et al., 2014. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother, 63(3):215-224.
[22]NiemanKM, KennyHA, PenickaCV, et al., 2011. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med, 17(11):1498-1503.
[23]PachynskiRK, ZabelBA, KohrtHE, et al., 2012. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med, 209(8):1427-1435.
[24]PagetS, 1889. The distribution of secondary growths in cancer of the breast. The Lancet, 133(3412):571-573.
[25]ReidBM, PermuthJB, SellersTA, 2017. Epidemiology of ovarian cancer: a review. Cancer Biol Med, 14(1):9-32.
[26]RennierK, ShinWJ, KrugE, et al., 2020. Chemerin reactivates PTEN and suppresses PD-L1 in tumor cells via modulation of a novel CMKLR1-mediated signaling cascade. Clin Cancer Res, 26(18):5019-5035.
[27]ReverchonM, CornuauM, RameC, et al., 2012. Chemerin inhibits IGF-1-induced progesterone and estradiol secretion in human granulosa cells. Hum Reprod, 27(6):1790-1800.
[28]ShinWJ, PachynskiRK, 2018. Chemerin modulation of tumor growth: potential clinical applications in cancer. Discov Med, 26(141):31-37.
[29]SteeleCB, ThomasCC, HenleySJ, et al., 2017. Vital signs: trends in incidence of cancers associated with overweight and obesity—United States, 2005‒2014. MMWR Morb Mortal Wkly Rep, 66(39):1052-1058.
[30]TreeckO, BuechlerC, OrtmannO, 2019. Chemerin and cancer. Int J Mol Sci, 20(15):3750.
[31]WangCH, WuWKK, LiuXD, et al., 2014. Increased serum chemerin level promotes cellular invasiveness in gastric cancer: a clinical and experimental study. Peptides, 51:131-138.
[32]WangZM, AguilarEG, LunaJI, et al., 2019. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med, 25(1):141-151.
[33]WiseHM, HermidaMA, LeslieNR, 2017. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond), 131(3):197-210.
[34]ZhangJ, JinHC, ZhuAK, et al., 2014. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides, 61:7-11.
Open peer comments: Debate/Discuss/Question/Opinion
<1>